These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 8720589)

  • 1. Semotiadil improves survival of rats with monocrotaline-induced pulmonary hypertension: comparison with diltiazem.
    Takahashi T; Kanda T; Imai S; Suzuki T; Kobayashi I; Murata K
    Eur J Pharmacol; 1996 Jan; 295(2-3):229-34. PubMed ID: 8720589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Semotiadil inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension.
    Takahashi T; Kanda T; Imai S; Suzuki T; Kobayashi I; Murata K
    Cardiovasc Drugs Ther; 1995 Dec; 9(6):809-14. PubMed ID: 8850386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amlodipine inhibits the development of right ventricular hypertrophy and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension.
    Takahashi T; Kanda T; Imai S; Suzuki T; Kobayashi I; Nagai R
    Res Commun Mol Pathol Pharmacol; 1996 Jan; 91(1):17-32. PubMed ID: 8824928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of semotiadil fumarate, a novel calcium antagonist, on blood pressure and heart rate in conscious spontaneously hypertensive rats.
    Kanda A; Hashimoto H
    Jpn J Pharmacol; 1993 Sep; 63(1):121-4. PubMed ID: 8271524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelin converting enzyme inhibitor protects development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension.
    Takahashi T; Kanda T; Inoue M; Sumino H; Kobayashi I; Iwamoto A; Nagai R
    Life Sci; 1998; 63(10):PL137-43. PubMed ID: 9734710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of olmesartan medoxomil in the rat monocrotaline model of pulmonary hypertension.
    Kato T; Nasu T; Sonoda H; Ito KM; Ikeda M; Ito K
    J Cardiovasc Pharmacol; 2008 Jan; 51(1):18-23. PubMed ID: 18209564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
    Guerard P; Rakotoniaina Z; Goirand F; Rochette L; Dumas M; Lirussi F; Bardou M
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Sep; 373(6):401-14. PubMed ID: 16896805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological profile of semotiadil fumarate, a novel calcium antagonist, in rat experimental angina model.
    Mori T; Ishigai Y; Fukuzawa A; Chiba K; Shibano T
    Br J Pharmacol; 1995 Sep; 116(1):1668-72. PubMed ID: 8564235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension.
    Takahashi T; Kanda T; Inoue M; Suzuki T; Kobayashi I; Kodama K; Nagai R
    Life Sci; 1996; 59(23):PL 371-7. PubMed ID: 8950302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel benzothiazine Ca2+ channel antagonist, semotiadil, inhibits cardiac L-type Ca2+ currents.
    Koidl B; Miyawaki N; Tritthart HA
    Eur J Pharmacol; 1997 Mar; 322(2-3):243-7. PubMed ID: 9098694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of semotiadil, a novel Ca2+ channel antagonist, on the electrical activity of Langendorff-perfused guinea pig hearts in comparison with diltiazem, amlodipine and nifedipine.
    Stark G; Kasper K; Stark U; Miyawaki N; Decrinis M; Tritthart HA
    Eur J Pharmacol; 1995 Nov; 286(1):71-8. PubMed ID: 8566153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effects of drag-reducing polymers in a rat model of monocrotaline-induced pulmonary hypertension.
    Wang Y; Hu F; Mu X; Wu F; Yang D; Zheng G; Sun X; Gong K; Zhang Z
    Biorheology; 2016 Jan; 53(1):13-22. PubMed ID: 26889655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats.
    Nishida M; Hasegawa Y; Tanida I; Nakagawa E; Inaji H; Ohkita M; Matsumura Y
    Eur J Pharmacol; 2009 Jul; 614(1-3):70-6. PubMed ID: 19379725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Ca2+ channel blockers on arterial hypertension and heart ischaemic lesions induced by chronic blockade of nitric oxide in the rat.
    de Oliveira CF; Nathan LP; Metze K; Moreno H; de Luca IM; Sucupira M; Zatz R; Zappellini A; Antunes E; de Nucci G
    Eur J Pharmacol; 1999 Jun; 373(2-3):195-200. PubMed ID: 10414439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.
    Rakotoniaina Z; Guerard P; Lirussi F; Goirand F; Rochette L; Dumas M; Bardou M
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):195-206. PubMed ID: 17102939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sandostatin inhibits development of medial proliferation of pulmonary arteries in a rat model of pulmonary hypertension.
    Takahashi T; Kanda T; Imai S; Suzuki T; Murata K
    Life Sci; 1995; 57(8):PL91-5. PubMed ID: 7637546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic infusion of adrenomedullin reduces pulmonary hypertension and lessens right ventricular hypertrophy in rats administered monocrotaline.
    Yoshihara F; Nishikimi T; Horio T; Yutani C; Takishita S; Matsuo H; Ohe T; Kangawa K
    Eur J Pharmacol; 1998 Aug; 355(1):33-9. PubMed ID: 9754936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.
    Schäfer S; Ellinghaus P; Janssen W; Kramer F; Lustig K; Milting H; Kast R; Klein M
    Cardiovasc Res; 2009 Apr; 82(1):30-9. PubMed ID: 19131365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism.
    Pei Y; Ma P; Wang X; Zhang W; Zhang X; Zheng P; Yan L; Xu Q; Dai G
    Eur J Pharmacol; 2011 Sep; 666(1-3):165-72. PubMed ID: 21641341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bucindolol improves right ventricle function in rats with pulmonary arterial hypertension through the reversal of autonomic imbalance.
    Lima-Seolin BG; Colombo R; Bonetto JHP; Teixeira RB; Donatti LM; Casali KR; Godoy AEG; Litvin IE; Schenkel PC; Rosa Araujo ASD; Belló-Klein A
    Eur J Pharmacol; 2017 Mar; 798():57-65. PubMed ID: 28011346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.